Why are pluripotent stem cells that have mutations to block the production of microRNAs unable to differentiate?
Maciej Maselko tells us about the troubles with public opinion of GMOs and how synthetic incompatibility may be the answer
A flexible Food and Drug Administration has once again rescued a biotech company seeking a drug approval based on flawed clinical trial data.
Gilead Sciences’ gene therapy that uses a patient’s own genetically modified immune cells to treat certain types of non-Hodgkin lymphoma has been approved.
Scientists have for the first time shown that a novel compound effectively suppresses production of HIV virus in chronically infected cells.
“Developing New Treatment Options for Unmet Medical Needs is the Cause That Inspires Us” – Julia Brown
Julia Brown explains why high standards of performance and high standards of ethical behaviour are essential to be successful in pharma.
Spark Therapeutic’s Luxturna, a gene therapy for a rare, genetic form of blindness, will be reviewed by a U.S. Food and Drug Administration panel this week.